Vir enrols first subject in Phase III programme to assess CHD therapy

by | Mar 14, 2025 | Clinical Trials | 0 comments

​ 

Vir Biotechnology has enrolled the first subject in the Phase III ECLIPSE registrational programme of tobevibart plus elebsiran.

 Vir Biotechnology has enrolled the first subject in the Phase III ECLIPSE registrational programme of tobevibart plus elebsiran. 

Submit a Comment

Your email address will not be published. Required fields are marked *